Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780094 | 0.90 | BACE2 (0.40) | BACE2CNR2VNN1RORCJAK1 | |
| SCHEMBL2807472 | 0.88 | P2RX7 (0.39) | CNR2TRPA1 | |
| Hydrochloric Acid SCHEMBL2805225 | 0.87 | P2RX7 (0.39) | CNR2TRPA1 | |
| SCHEMBL2805697 | 0.86 | RAB9A (0.41) | CNR2 | |
| SCHEMBL2808542 | 0.86 | CNR2 (0.41) | CNR2RORCTRPA1 | |
| SCHEMBL2811244 | 0.85 | CNR2 (0.41) | CNR2VNN1JAK3 | |
| SCHEMBL13128612 | 0.83 | BDKRB1 (0.38) | BACE2CNR2VNN1RORCJAK1 | |
| Trifluoroacetic Acid SCHEMBL2809036 | 0.83 | RAB9A (0.38) | CNR2RORC | |
| Trifluoroacetic Acid SCHEMBL2813582 | 0.83 | CNR2 (0.39) | CNR2RORC | |
| SCHEMBL2811328 | 0.80 | MEN1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | BACE2 4192/4885CNR2 882/4885VNN1 3094/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | BACE2 4192/4885CNR2 882/4885VNN1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.